Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India
Januvia Generic Sees Strong Competition
Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.
You may also be interested in...
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?
Two years after denying sell-off plans, Unichem Laboratories is divesting its branded business in India and Nepal to peer Torrent for around $558m. The deal catapults Torrent to the top league on the domestic market and also sets the tone for potential consolidation in the Indian pharma space at more realistic valuations.
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India